S&P 500   3,319.86 (+0.13%)
DOW   27,425.10 (+0.50%)
QQQ   271.48 (-0.37%)
AAPL   111.60 (-0.19%)
MSFT   206.18 (-0.60%)
FB   256.80 (+0.80%)
GOOGL   1,446.96 (-0.88%)
AMZN   3,103.36 (-0.82%)
NVDA   502.16 (-0.66%)
TSLA   402.75 (-5.06%)
BABA   276.03 (+0.27%)
CGC   15.84 (-1.25%)
GE   6.36 (+1.76%)
MU   51.15 (+2.92%)
AMD   77.01 (-0.89%)
T   28.58 (+0.25%)
F   6.89 (+1.62%)
ACB   5.91 (-19.26%)
GILD   63.58 (+0.28%)
NFLX   488.15 (-0.61%)
DIS   126.80 (-0.32%)
BAC   24.13 (+0.79%)
BA   159.70 (+1.85%)
S&P 500   3,319.86 (+0.13%)
DOW   27,425.10 (+0.50%)
QQQ   271.48 (-0.37%)
AAPL   111.60 (-0.19%)
MSFT   206.18 (-0.60%)
FB   256.80 (+0.80%)
GOOGL   1,446.96 (-0.88%)
AMZN   3,103.36 (-0.82%)
NVDA   502.16 (-0.66%)
TSLA   402.75 (-5.06%)
BABA   276.03 (+0.27%)
CGC   15.84 (-1.25%)
GE   6.36 (+1.76%)
MU   51.15 (+2.92%)
AMD   77.01 (-0.89%)
T   28.58 (+0.25%)
F   6.89 (+1.62%)
ACB   5.91 (-19.26%)
GILD   63.58 (+0.28%)
NFLX   488.15 (-0.61%)
DIS   126.80 (-0.32%)
BAC   24.13 (+0.79%)
BA   159.70 (+1.85%)
S&P 500   3,319.86 (+0.13%)
DOW   27,425.10 (+0.50%)
QQQ   271.48 (-0.37%)
AAPL   111.60 (-0.19%)
MSFT   206.18 (-0.60%)
FB   256.80 (+0.80%)
GOOGL   1,446.96 (-0.88%)
AMZN   3,103.36 (-0.82%)
NVDA   502.16 (-0.66%)
TSLA   402.75 (-5.06%)
BABA   276.03 (+0.27%)
CGC   15.84 (-1.25%)
GE   6.36 (+1.76%)
MU   51.15 (+2.92%)
AMD   77.01 (-0.89%)
T   28.58 (+0.25%)
F   6.89 (+1.62%)
ACB   5.91 (-19.26%)
GILD   63.58 (+0.28%)
NFLX   488.15 (-0.61%)
DIS   126.80 (-0.32%)
BAC   24.13 (+0.79%)
BA   159.70 (+1.85%)
S&P 500   3,319.86 (+0.13%)
DOW   27,425.10 (+0.50%)
QQQ   271.48 (-0.37%)
AAPL   111.60 (-0.19%)
MSFT   206.18 (-0.60%)
FB   256.80 (+0.80%)
GOOGL   1,446.96 (-0.88%)
AMZN   3,103.36 (-0.82%)
NVDA   502.16 (-0.66%)
TSLA   402.75 (-5.06%)
BABA   276.03 (+0.27%)
CGC   15.84 (-1.25%)
GE   6.36 (+1.76%)
MU   51.15 (+2.92%)
AMD   77.01 (-0.89%)
T   28.58 (+0.25%)
F   6.89 (+1.62%)
ACB   5.91 (-19.26%)
GILD   63.58 (+0.28%)
NFLX   488.15 (-0.61%)
DIS   126.80 (-0.32%)
BAC   24.13 (+0.79%)
BA   159.70 (+1.85%)
Log in
OTCMKTS:LIXT

Lixte Biotechnology Stock Forecast, Price & News

$1.18
-0.01 (-0.84 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.18
Now: $1.18
$1.18
50-Day Range
$1.00
MA: $1.17
$1.20
52-Week Range
$0.57
Now: $1.18
$1.35
Volume1,100 shs
Average Volume4,844 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher's disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company was founded in 2005 and is based in East Setauket, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:LIXT
Previous SymbolNASDAQ:LIXT
CUSIPN/A
Phone+1-631-8307092

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$1.18
-0.01 (-0.84 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIXT News and Ratings via Email

Sign-up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lixte Biotechnology (OTCMKTS:LIXT) Frequently Asked Questions

How has Lixte Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?

Lixte Biotechnology's stock was trading at $0.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LIXT shares have increased by 32.6% and is now trading at $1.18.
View which stocks have been most impacted by COVID-19
.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings Inc (OTCMKTS:LIXT) announced its earnings results on Friday, November, 4th. The company reported ($0.01) earnings per share (EPS) for the quarter.
View Lixte Biotechnology's earnings history
.

Who are some of Lixte Biotechnology's key competitors?

What other stocks do shareholders of Lixte Biotechnology own?

Who are Lixte Biotechnology's key executives?

Lixte Biotechnology's management team includes the following people:
  • Dr. John S. Kovach, Founder, Chairman, Pres, CEO & CFO (Age 82)
  • Mr. Gil N. Schwartzberg, Consultant
  • Dr. Francis Johnson Ph.D., Consultant

What is Lixte Biotechnology's stock symbol?

Lixte Biotechnology trades on the OTCMKTS under the ticker symbol "LIXT."

How do I buy shares of Lixte Biotechnology?

Shares of LIXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lixte Biotechnology's stock price today?

One share of LIXT stock can currently be purchased for approximately $1.18.

What is Lixte Biotechnology's official website?

The official website for Lixte Biotechnology is www.lixte.com.

How can I contact Lixte Biotechnology?

Lixte Biotechnology's mailing address is 248 Route 25A, No. 2, EAST SETAUKET, NY 11733, United States. The company can be reached via phone at +1-631-8307092.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.